Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Novo Nordisk is strengthening its position in the GLP-1 market with a successful Wegovy pill launch and expanding its diabetes treatment offerings in China. While Eli Lilly remains a strong competitor, other companies like Viking Therapeutics are developing next-generation weight-loss drugs, indicating increasing competition and innovation in the obesity market.